The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-α antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.